RESEARCH ARTICLE

Increased Hypermethylation of Glutathione S-Transferase P1, DNA-Binding Protein Inhibitor, Death Associated Protein Kinase and Paired Box Protein-5 Genes in Triple-Negative Breast Cancer Saudi Females

Mohamed M Hafez1, Othman A Al-Shabanah1, Salim S Al-Rejaie1, Naif O Al-Harbi1, Zeinab K Hassan2, Abdulmalik Alsheikh3, Abdurrahman I Al Theyab4, Meshan L Aldelemy5, Mohamed M Sayed-Ahmed1*

Abstract

Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) with higher metastatic rate and both local and systemic recurrence compared to non-TNBC. The generation of reactive oxygen species (ROS) secondary to oxidative stress is associated with DNA damage, chromosomal degradation and alterations of both hypermethylation and hypomethylation of DNA. This study concerns differential methylation of promoter regions in specific groups of genes in TNBC and non-TNBC Saudi females in an effort to understand whether epigenetic events might be involved in breast carcinogenesis, and whether they might be used as markers for Saudi BCs. Methylation of glutathione S-transferase P1 (GSTP1), T-cadherin (CDH13), Paired box protein 5 (PAX5), death associated protein kinase (DAPK), twist-related protein (TWIST), DNA-binding protein inhibitor (ID4), High In Normal-1 (HIN-1), cyclin-dependent kinase inhibitor 2A (p16), cyclin D2 and retinoic acid receptor-β (RARβ1) genes was analyzed by methylation specific polymerase chain reaction (MSP) in 200 archival formalin-fixed paraffin embedded BC tissues divided into 3 groups; benign breast tissues (20), TNBC (80) and non-TNBC (100). The relationships between methylation status, and clinical and pathological characteristics of patients and tumors were assessed. Higher frequencies of GSTP1, ID4, TWIST, DAPK, PAX5 and HIN-1 hypermethylation were found in TNBC than in non-TNBC. Hypermethylation of GSTP1, CDH13, ID4, DAPK, HIN-1 and PAX5 increased with tumor grade increasing. Other statistically significant correlations were identified with studied genes. Data from this study suggest that increased hypermethylation of GSTP1, ID4, TWIST, DAPK, PAX5 and HIN-1 genes in TNBC than in non-TNBC can act as useful biomarker for BCs in the Saudi population. The higher frequency of specific hypermethylated genes paralleling tumor grade, size and lymph node involvement suggests contributions to breast cancer initiation and progression.

Keywords: Breast cancer - TNBC - Non-TNBC - oxidative stress - DNA methylation - Saudi Arabia

Asian Pac J Cancer Prev, 16 (2), 541-549

Introduction

Breast cancer (BC) is the most common malignancy among females worldwide and represents 22% of all newly diagnosed female cancers annually in Saudi Arabia with 60-80% of the patients are diagnosed at advanced stage (Al Tamimi et al., 2010; Aboserea et al., 2011). Triple Negative BC (TNBC) is a subtype of BC is characterized by the absence of hormone receptors expression of progesterone (PR), estrogen (ER) and human epidermal growth factor receptor-2 (HER-2) and represents 10-17% of all BC patients (Yuan et al., 2014). It is well documented that tumor development requires phenotypic changes associated with initiation, promotion and progression phases carcinogenesis (Vincent and Gatenby, 2008). Genes in each of these phases acquire alterations in their transcriptional activity that are associated either with hypermethylation-induced transcriptional repression such as tumor suppressor genes or hypomethylation-induced activation in oncogenes (Panayiotidis, 2014). Comprehensive gene analyses on BC tissues discovered the expression profiles of genes and resulted in identification of mRNAs that are up- and down-regulated in breast carcinomas compared to normal
Mohamed M Hafez et al
Asian Pacific Journal of Cancer Prevention, Vol 16, 2015

DNA hypermethylation studies in breast carcinoma focused on the methylation status of tumor-related genes in invasive BC compared to normal breast tissue (Gheibi et al., 2012; Sturgeon et al., 2012; Yamamoto et al., 2012). Several studies identified specific genes targets epigenetic including tumor suppressor gene such as P16 (Feng et al., 2010; Askari et al., 2013; Khor et al., 2013), transcription factors such as TWIST, PAX5 and ID4 (Palmasano et al., 2003; Noetzel et al., 2008; Mishra et al., 2010; Cho et al., 2012), receptors such RARβ (Flamini et al., 2014), cytokines such HIN-1 (Krop et al., 2001; Dai et al., 2014), cell cycle regulators such as Cyclin D2 (Henrique et al., 2006), adhesion molecules such as CDH13 (Xu et al., 2012), gene associated with DNA apoptosis such as DAPK (Das and Singal, 2004), gene involved in detoxification pathway of xenobiotic such as GSTP1 (Asemi et al., 2012).

These genes helped to explain the molecular detection and pathogenesis of BC as even small amounts of methylated sequences are readily detectable. As little information is available about DNA methylation status in TNBC, therefore this study investigates the differential methylation of the promoter region in specific group of genes in TNBC and non-TNBC Saudi’s females using MSP in an effort to understand the contribution of this epigenetic event in breast carcinogenesis, and whether it can be used as marker. The selected genes, those play a role in development and progression of BC, fall into different groups: genes commonly methylated in BC (including cyclin D2, CDH13 and RARβ1, P16, HIN-1), genes associated with transcription factors (such as TWIST, PAX5 and ID4), genes associated with DNA apoptosis such as (DAPK) and gene involved in detoxification of xenobiotics (such as GSTP1).

Materials and Methods

This study was conducted in compliance with Helsinki Declaration and has been approved by the Ethical Committee, College of Medicine, King Saud University. The present study based on 200 Saudi females living in the province of Riyadh, Kingdom of Saudi Arabia, with primary invasive breast cancer whom had undergone surgery from January 2009 to January 2011 (retrospective analysis). Two hundred formalin-fixed paraffin-embedded (FFPE) breast carcinoma tissues were collected from Pathology Department, College of Medicine, King Saud University (135 cases) and Pathology Department, Al-Shemissy Hospital (65 cases), Riyadh, Saudi Arabia. Inclusion criteria was archived primary breast tumors (T-stage 1-3 invasive ductal carcinoma of NOS type) assessed by immunohistochemistry for expression of ER, PR and HER-2 at the time of diagnosis. Whole tumor sections were examined to carefully review the histological characteristics of each tissue specimen.

Study design, demographic and clinical characteristics

A total of 200 FFPE samples were classified into three separate groups. Group 1 (Control): included 20 FFPE benign breast tissues and served as control. Group 2 (non-TNBC): included 100 FFPE samples from non-TNBC patients. Group 3 (TNBC) included 80 FFPE samples from TNBC patients. In non-TNBC patients, the mean age at diagnosis was 48 years (SE 1.12; range 24 to 91 years).

Twenty-two cases were less than 40 years, 46 cases were 40-50 years and 32 cases were above 50 years. All Non-TNBC cases had invasive ductal carcinoma with 65 cases had grade III, 29 had grade II and 6 had grade I. Moreover, more than 50 % of non-TNBC cases (53) were positive for ER, PR and HER-2-neu, 19 cases were ER and PR negative and HER-2-neu positive, 15 cases were ER and PR positive and HER-2-neu negative and 13 cases were ER and HER-2-neu positive and PR negative. On the other hand, in TNBC patients, the mean age at diagnosis was 42.5 years (SE 1.2; range 28 to 70 years). A total of 36 cases were less than 40 years, 28 cases were 40-50 years and 16 cases were above 50 years. Regarding the histological categories, all TNBC cases had invasive ductal carcinoma with 35 cases had grade III, 36 had grade II and 9 had grade I. Moreover, all TNBC cases (80) were negative for ER, PR and HER-2-neu. These selected characteristics of the patients showed that there is no significant difference between TNBC and Non-TNBC cases regarding the mean age, histological categories and histological grade of the tumors.

DNA extraction and bisulfate treatment

All the FFPE samples were thin sectioned at 8 µm thicknesses using Leica Microtome (Manual Rotary Microtome RM2235). Tissue sections were floated in a DEPC-treated water bath then picked up on clean glass slides and allowed to air dry at 4°C, after which they were stored at -20°C until used. The composition of the unstained slides from each archival FFPE tissue block studied was confirmed by histopathologic examination of surrounding hematoxylin and eosin (H and E)-stained sections. For each tumor, the lesion was identified on an initial H and E-stained section and confirmed to remain on a serial H and E section taken following preparation of unstained sections for micro-dissection and nucleic acid extraction.

Hence, the lesion was documented to be present on stained sections taken before and after preparation of the analyzed unstained sections. For DNA extraction, two 8µm tissue sections were examined and selected areas of tumor tissues were removed from the slides using scalpel and placed directly into sterile 2ml Eppendorf tubes. DNA was extracted after micro-dissection using Recover All total Nucleic Acid Isolation Kit (Ambion, Life Technologies, USA) following the manufacturer instructions. Tissue sections were deparaffinized followed by digestion using buffer and proteases. Nucleic acids were isolated with additive/ethanol mixture followed by transfer to the column and elution. Quantity and quality of extracted DNA as characterized using a UV spectrophotometer (Nanodrop 8000, thermo scientific, USA).

Sodium bisulfite treatment of DNA

Tissue DNA was treated with sodium bisulfate using...
EpiTect Bisulfite Kits (QIAGEN, Germany) according to the manufacturers’ instructions. This process converts nonmethylated cytosine residues to uracil, whereas methylated cytosines remain unchanged. All solutions were prepared fresh. Briefly 50 µl DNA (1-2 µg) extract was incubated with 140 µl of bisulfite reaction components at room temperature for 5 min followed by denaturation at 95°C for 5 min, 60°C for 25 min, 95°C for 5 min, 60°C for 85 min, 95°C for 5 min and finally 60°C for 175 min. BL buffer containing 10 µg/ml carrier RNA was mix with bisulfite converted DNA and transfer to EpiTect spin columns. After washing, 20 µl of Elution Buffer was added onto the center of each membrane then the DNA was aliquoted and stored until used at -80°C.

Methylation-specific polymerase chain reaction (MSP) using real time PCR

CpG islands of CDH13, GSTP1, ID4, p16, TWIST, Cyclin D2, PAX5, DAPK, HIN-1 and RARβ1 genes were examined by MSP (TAKARA, BIO INC, Japan). Forward and reverse primers were synthesized (Metabion, Germany) corresponding to the predicted sequence of methylated or unmethylated genomic DNA after sodium bisulfate treatment (Table 1). For reaction, 1 µl sodium bisulfite-treated DNA was added to 24 µl reaction buffer containing 0.3 µM of forward and reverse primers specific to unmethylated and methylated DNA sequences, 1.2 µl of MSP enzyme, 0.5µl of 100X SYBRGreen1 and 1 µl of 50X of ROX reference Dye. The cycling conditions were 95°C for 5 min, followed by 45 cycles of 98°C for 30 sec, 55°C for 30 sec and 72°C for 45 sec. Universally methylated DNA and unmethylated DNA (CHEMICON International, Temecula, CA, USA) were used as controls for MSP. Following amplification melting curve analysis was performed to identify the presence of primer dimers and analyzed the reaction specificity. MSP products were separated electrophoretically on 3% agarose. Single band of methylated and/or unmethylated genes were visualized by photo-documentation system (syngene bio imaging, USA) (Figure1).

Statistically analysis

The exact chi-square test (SPSS, version 15.0) was used to analyze the association between methylation frequencies of all genes and to compare the tumor characteristics (e.g., age, tumor grade, tumor size) in breast cancer groups. P values <0.05 were considered to be statistically significant.

Results

This study investigates the role of promoter hypermethylation of ten genes (GSTP1, CDH13, RARβ1, TWIST, P16, PAX5, ID4, cyclin D2, HIN-1 and DAPK) in TNBC and non-TNBC cases. In the overall cases, 12 (15%) of TNBC, 13 (13%) of non-TNBC and 17 (85%) of benign tissues did not show hypermethylation in any of the studied genes. In benign breast tissue, some degree of hypermethylation was detected in four genes (ID4, TWIST, cyclinD2, and DAPK). Using hierarchical clustering, we identified significant similarity in methylation patterns of genes in TNBC and Non-TNBC breast cancer tissues as shown in Figure 2.

![Figure 1. Representative Examples of Methylation-Specific PCR Assays of the Methylated (M) and Unmethylated (U) Genes](image-url)
In TNBC cases, significant hypermethylation (p<0.05) at high frequencies were observed in GSTP1 72.5%, CDH13 33.8% cases (Table 2), ID4 73.8%, TWIST 48.8% cases (Table 3), HIN-1 65% and DAPK 77.5% cases (Table 4 and Figure 3A) compared to 31%, 19%, 43%, 34%, 42% and 43% respectively in non-TNBC (Figure 3B). In benign breast tissues, two cases showed hypermethylation in six out of ten studied genes while the third case showed hypermethylation in 9 genes.

In TNBC, DAPK gene hypermethylation was significantly increased with tumor size from 77.8% in <2 cm to 84.6% in >2 cm compared to 33.3% and 46.8% in Non-TNBC respectively. In TNBC, DAPK gene hypermethylation was significantly associated also with grade increasing 77.8% in grade-I, 69.4% in grade-II and 85.7% in grade-III cases compared to 33.3%, 44.8% and 43.1% respectively in non-TNBC. According to LN status in TNBC, DAPK gene was significant increase from 74.3% in LN negative to 80% in LN positive compared to 41.2% and 46.9% respectively in non-TNBC (Table 4).

ID4 gene hypermethylation was significantly increased with increasing tumor size 84.6% in >2 cm compared to 72.2% in <2 cm in TNBC compared to 46.8% and 33.3% respectively in non-TNBC (Table 3). There was significant increase in association with LN status in TNBC 77.8% in LN positive and 68.6% in LN negative compared to 49.9% and 41.2% respectively in non-TNBC. With regard to tumor grade, a significant hypermethylation of ID4 gene (66.7% and 80%) was observed in grade II and III in TNBC compared to Non-TNBC.

GSTP1 gene hypermethylation in TNBC was significantly associated with tumor grade 66.7% in grade-I, 75% in grade-II and 71.4% in grade-III compared to 16.7%, 27.6 and 33.8% respectively in non-TNBC (Table 2). In relation to LN status, no significant changes were observed in both groups. Concerning tumor size, GSTP1 gene hypermethylation was significantly increased with tumor size in TNBC compared to Non-TNBC.

Cyclin D2 hypermethylation was significantly higher in TNBC cases, significant hypermethylation (p<0.05) at high frequencies were observed in GSTP1 72.5%, CDH13 33.8% cases (Table 2), ID4 73.8%, TWIST 48.8% cases (Table 3), HIN-1 65% and DAPK 77.5% cases (Table 4 and Figure 3A) compared to 31%, 19%, 43%, 34%, 42% and 43% respectively in non-TNBC (Figure 3B). In benign breast tissues, two cases showed hypermethylation in six out of ten studied genes while the third case showed hypermethylation in 9 genes.

In TNBC, DAPK gene hypermethylation was significantly increased with tumor size from 77.8% in <2 cm to 84.6% in >2 cm compared to 33.3% and 46.8% in Non-TNBC respectively. In TNBC, DAPK gene hypermethylation was significantly associated also with grade increasing 77.8% in grade-I, 69.4% in grade-II and 85.7% in grade-III cases compared to 33.3%, 44.8% and 43.1% respectively in non-TNBC. According to LN status in TNBC, DAPK gene was significant increase from 74.3% in LN negative to 80% in LN positive compared to 41.2% and 46.9% respectively in non-TNBC (Table 4).

ID4 gene hypermethylation was significantly increased with increasing tumor size 84.6% in >2 cm compared to 72.2% in <2 cm in TNBC compared to 46.8% and 33.3% respectively in non-TNBC (Table 3). There was significant increase in association with LN status in TNBC 77.8% in LN positive and 68.6% in LN negative compared to 49.9% and 41.2% respectively in non-TNBC. With regard to tumor grade, a significant hypermethylation of ID4 gene (66.7% and 80%) was observed in grade II and III in TNBC compared to Non-TNBC.

GSTP1 gene hypermethylation in TNBC was significantly associated with tumor grade 66.7% in grade-I, 75% in grade-II and 71.4% in grade-III compared to 16.7%, 27.6 and 33.8% respectively in non-TNBC (Table 2). In relation to LN status, no significant changes were observed in both groups. Concerning tumor size, GSTP1 gene hypermethylation was significantly increased with tumor size in TNBC compared to Non-TNBC.

ID4 gene hypermethylation was significantly increased with increasing tumor size 84.6% in >2 cm compared to 72.2% in <2 cm in TNBC compared to 46.8% and 33.3% respectively in non-TNBC (Table 3). There was significant increase in association with LN status in TNBC 77.8% in LN positive and 68.6% in LN negative compared to 49.9% and 41.2% respectively in non-TNBC. With regard to tumor grade, a significant hypermethylation of ID4 gene (66.7% and 80%) was observed in grade II and III in TNBC compared to Non-TNBC.

GSTP1 gene hypermethylation in TNBC was significantly associated with tumor grade 66.7% in grade-I, 75% in grade-II and 71.4% in grade-III compared to 16.7%, 27.6 and 33.8% respectively in non-TNBC (Table 2). In relation to LN status, no significant changes were observed in both groups. Concerning tumor size, GSTP1 gene hypermethylation was significantly increased with tumor size in TNBC compared to Non-TNBC.

Cyclin D2 hypermethylation was significantly higher in TNBC cases, significant hypermethylation (p<0.05) at high frequencies were observed in GSTP1 72.5%, CDH13 33.8% cases (Table 2), ID4 73.8%, TWIST 48.8% cases (Table 3), HIN-1 65% and DAPK 77.5% cases (Table 4 and Figure 3A) compared to 31%, 19%, 43%, 34%, 42% and 43% respectively in non-TNBC (Figure 3B). In benign breast tissues, two cases showed hypermethylation in six out of ten studied genes while the third case showed hypermethylation in 9 genes.

In TNBC, DAPK gene hypermethylation was significantly increased with tumor size from 77.8% in <2 cm to 84.6% in >2 cm compared to 33.3% and 46.8% in Non-TNBC respectively. In TNBC, DAPK gene hypermethylation was significantly associated also with grade increasing 77.8% in grade-I, 69.4% in grade-II and 85.7% in grade-III cases compared to 33.3%, 44.8% and 43.1% respectively in non-TNBC. According to LN status in TNBC, DAPK gene was significant increase from 74.3% in LN negative to 80% in LN positive compared to 41.2% and 46.9% respectively in non-TNBC (Table 4).

ID4 gene hypermethylation was significantly increased with increasing tumor size 84.6% in >2 cm compared to 72.2% in <2 cm in TNBC compared to 46.8% and 33.3% respectively in non-TNBC (Table 3). There was significant increase in association with LN status in TNBC 77.8% in LN positive and 68.6% in LN negative compared to 49.9% and 41.2% respectively in non-TNBC. With regard to tumor grade, a significant hypermethylation of ID4 gene (66.7% and 80%) was observed in grade II and III in TNBC compared to Non-TNBC.

GSTP1 gene hypermethylation in TNBC was significantly associated with tumor grade 66.7% in grade-I, 75% in grade-II and 71.4% in grade-III compared to 16.7%, 27.6 and 33.8% respectively in non-TNBC (Table 2). In relation to LN status, no significant changes were observed in both groups. Concerning tumor size, GSTP1 gene hypermethylation was significantly increased with tumor size in TNBC compared to Non-TNBC.

| Characteristics | TNBC | Non-TNBC |
|-----------------|------|----------|
| M %             |      |          |
| Age (year):     |      |          |
| <40 years       | 36   | 69.4*    |
| 41-50 years     | 28   | 78.6*    |
| >50 years       | 16   | 68.8*    |
| Tumor Grade:    |      |          |
| I               | 9    | 66.7*    |
| II              | 36   | 75*      |
| III             | 35   | 71.4*    |
| Lymphnode status: |    |          |
| positive        | 45   | 71.1*    |
| negative        | 35   | 74.3*    |
| Tumor size:     |      |          |
| Unknown         | 36   | 69.4    |
| <2 cm           | 18   | 72.2*   |
| >2 cm           | 26   | 76.9*   |

Data are presented as percentage methylation (M %), n = 100 and 80 for Non-TNBC and TNBC groups, respectively. * indicate significant change from Non-TNBC, using exact chi-square test (SPSS, version 15.0). P values ≤ 0.05 were considered statistically significant.
in tumor grade I (83%) in non-TNBC compared to 33.3% in TNBC groups. In both groups, there was no association between hypermethylation of cyclin D2 and tumor size. According to LN status, in non-TNBC was 21.9% in LN positive compared to 38.2% in LN negative while in TNBC no association was observed (Table 2).

CDH13 gene hypermethylation was insignificantly associated with grade increasing in TNBC grade-I 0%, grade-II 33.3% and grade-III 42.9% compared to 16.7%, 17.2% and 20% in non-TNBC and associated with tumor size, <2 cm (38.9%) compared to 30.8% in >2 cm compared to 16.7% and 19.4% respectively in non-TNBC. According to LN status, there was statistically significant observed in LN negative in TNBC (37.1%) compared to 17.6% in non-TNBC (Table 2).

RARβ1 gene hypermethylation was insignificantly increased with tumor size, in TNBC was 34.6% in tumor size >2 cm and 16.7% in those <2 cm compared to 24.2% and 37.5% respectively in non-TNBC. There was a decrease in this gene associated with LN status by 28.9% in LN positive and 20% in LN negative in TNBC compared to 21.9% and 27.9% respectively in non-TNBC (Table 2).

PAX5 gene hypermethylation was decreased with tumor size <2 cm and >2 cm from 61.1% to 53.8% in TNBC and increased in non-TNBC from 41.7% to 58.1% respectively. In TNBC, hypermethylation of PAX5 was associated with grade increasing 55.6% in grade-I, 52.8% in grade-II and 60% in grade-III compared to 66.7%, 62.1% and 47.7% respectively in non-TNBC. In relation to LN status, in TNBC hypermethylation was increased from 51.4% in LN negative to 60% in positive LN and decreased from 59.4% to 50% in non-TNBC, but this differences were statistically insignificant (Table 3).

TWIST gene hypermethylation was observed with high frequency in grade-I 55.6% in TNBC compared to 50% in non-TNBC. In addition, hypermethylation of TWIST gene was insignificantly increased with increasing tumor size, <2 cm 33.3% and >2 cm 50% in TNBC compared to 54.2% and 32.3% in TNBC respectively (Table 3).

HIN-1 gene hypermethylation was significantly increased in TNBC by 65.7% in grade-III compared to 33.8% in non-TNBC. In TNBC, HIN-1 gene hypermethylation was increased significantly 74.3% in LN negative and insignificantly 57.8% in LN positive.

Table 3. Correlation between Percentage Methylation (M %) of ID4, TWIST and PAX5 Genes and Clinico-pathological Features among Triple Negative and Non-triple Negative Breast Cancer Patients

| Characteristics | TNBC | Non-TNBC |
|-----------------|------:|---------:|
| Age (year):     |       |         |
| <40 years       | 36    | 32      |
| 41-50 years     | 28    | 21      |
| >50 years       | 16    | 39      |
| Grade Tumor:    |       |         |
| I               | 9     | 9       |
| II              | 36    | 40      |
| III             | 35    | 44      |
| Lymphnode status: |     |         |
| positive        | 45    | 40      |
| negative        | 35    | 50      |
| Tumor size:     |       |         |
| Unknown         | 38    | 43      |
| <2 cm           | 18    | 21      |
| >2 cm           | 26    | 29      |

Data are presented as percentage methylation (M %), n=100 and 80 for Non-TNBC and TNBC groups, respectively; * indicate significant change from Non-TNBC, using exact chi-square test (SPSS, version 15.0). P values ≤ 0.05 were considered statistically significant.
Table 4. Correlation between Percentage Methylation (M%) of P16 and HIN-1 genes and Clinico-pathological Features among Triple Negative and Non-triple Negative Breast Cancer Patients

| Characteristics       | TNBC                  | Non-TNBC               |
|-----------------------|-----------------------|------------------------|
|                       | M % 100 N 80 p16 HIN1 DAPK | M % 100 N 80 p16 HIN1 DAPK |
| Age (year):           |                       |                        |
| <40 years             | 36 47.2 58.3 80.6*    | 22 40.9 54.5 36.4      |
| 41-50 years           | 28 39.3 71.4* 78.6    | 46 43.5 43.5 54.3      |
| >50 years             | 16 25 68.8* 68.8*     | 32 34.4 31.2 31.2      |
| Tumor size:           |                       |                        |
| < 2 cm                | 18 27.8 66.7 77.8*    | 24 33.3 41.7 33.3      |
| > 2 cm                | 36 41.7 66.7 72.2     | 14 50 42.9 42.9        |
| Unknown               | 35 45.7 74.3* 74.3*   | 68 36.8 39.7 41.2      |
| Lymphnode status:     |                       |                        |
| positive              |                        |                        |
| negative              | 35 45.7 74.3* 74.3*   | 68 36.8 39.7 41.2      |
| Tumor Grade:          |                       |                        |
| I                     | 9 22.2 55.6 77.8*     | 6 33.3 33.3 33.3       |
| II                    | 36 47.2 66.7 69.4*    | 29 41.4 62.1 44.8      |
| III                   | 35 37.1 65.7* 85.7*   | 65 40 33.8 43.1        |

*Data are presented as percentage methylation (M%), n = 100 and 80 for Non-TNBC and TNBC groups, respectively. * indicate significant change from Non-TNBC, using exact chi-square test (SPSS, version 15.0). P values ≤ 0.05 were considered to be statistically significant.

compared to 36.8 % and 46.9%, respectively in Non-TNBC (Table 4).

P16 hypermethylation was insignificantly increased in TNBC with tumor size from 27.8% in tumor size <2 cm to 46.2% in >2 cm and from 33.3% to 40.3% respectively in non-TNBC. In TNBC, P16 hypermethylation was associated with grade increasing 22.2% in grade-I compared to 47.2% in grade-II. With regard to LN status, in non-TNBC P16 hypermethylation was 36.8% in LN negative and 46.9% in LN positive while in TNBC no association was observed (Table 4).

Discussion

Although several studies have demonstrated that DNA hypermethylation plays an important role in breast carcinogenesis (Cho et al., 2009; Tan et al., 2012), little information is available about DNA methylation status in TNBC. Accordingly, this study investigates the differential methylation of the promoter region in specific group of genes in TNBC and Non-TNBC Saudi’s females. Our results detected overall higher methylation frequencies of GSTP1, HIN-1, TWIST, ID4, PAX5 and DAPK genes in TNBC compared to non-TNBC. The promoter hypermethylation of these genes can be used as tumor-specific biomarker in TNBC Saudi’s patients.

Death associated protein kinase (DAPK) gene is a positive mediator for programmed cell death induced by γ-interferon (Suijkerbuijk et al., 2010). The loss of DAPK gene expression was associated with aggressive and metastatic phenotype in many tumor types primarily by promoter hypermethylation (Suijkerbuijk et al., 2010). In the present study, DAPK gene was hypermethylated at highest frequencies in TNBC compared to non-TNBC. In addition, we found strong and higher association between DAPK hypermethylation and tumor grade and size in both TNBC and non-TNBC. Similarly in patients with head and neck cancer, Sanchez-Cespedes et al. (2000) observed an association between DAPK methylation and tumor size (Sanchez-Cespedes et al., 2000). They also found frequently lost in the expression of DAPK gene and protein in human cancer often as a result of silencing by DNA methylation. Similarly, higher hypermethylation of DAPK gene was observed in more advanced stage of cervical cancer (Narayan et al., 2003). Accordingly, one can anticipate that this hypermethylation of DAPK gene with the consequent lose of its expression may play a role in breast carcinogenesis.

ID4 gene has regulative functions for cell differentiation and growth. Inactivation of ID4 gene via promoter hypermethylation has been shown in human tumors such as breast cancer (Noetzel et al., 2008). Data presented here demonstrated differential increase of ID4 hypermethylation in TNBC than Non-TNBC cases. In addition, the incidence of ID4 hypermethylation was increased with increasing tumor size and the number of LN positive in both TNBC and non-TNBC cases. Accordingly, our results suggested that hypermethylation of ID4 as a potential tumor suppressive gene may play an important role in BC development and can be used as a genetic marker for prediction of early metastasis that could explain the aggressiveness of TNBC compared to non-TNBC. Our results are consistent with the data presented by Umetani et al. which have demonstrated a significant lower mRNA level of ID4 in primary breast cancer specimens and indicated that the ID4 transcription was inactivated by promoter hypermethylation in clinical breast cancer specimens (Umetani et al., 2005).

Glutathione S-transferase P1 (GSTP1) is a polymorphic gene encoding active, functionally different variant proteins that are thought to function in xenobiotic metabolism and play a role in susceptibility to cancer, and other diseases. As different types of diet has been implicated in breast cancer, the loss of GSTP1 secondary to hypermethylation lead to impaired of cellular defenses leading to increasing genome damage and cancer.
development (Wang et al., 2014). In our study, high frequency of GSTP1 hypermethylation was significant associated with TNBC. This finding is important as GST gene is a family of enzymes that detoxify hydrophobic electrophiles, which include carcinogens that have been occupied with variety of cancers (Wang et al., 2014). The detection of GSTP1 hypermethylation was not correlated with other clinical parameters such as age, tumor size and LN status which are consistent with previous study (Jentzmik et al., 2012). Hypermethylation of GSTP1 with high frequency in different tumor grade was pathologically correlated with early stage of cancer.

In human breast cancer, hypermethylation of tumor suppressor gene is clearly observed. HIN-1 gene, a putative cytokine, is down-regulated in breast cancer tissues by promoter hypermethylation (Park et al., 2011). The present study showed increased in the frequency of HIN-1 gene hypermethylation in TNBC than Non-TNBC patients with higher incidence in LN positive in both groups. Other study found frequent methylation of HIN-1, CDH13 and RARβ2 genes in primary breast cancer and in metastatic LN but not in normal breast tissues (Feng et al., 2010). Our results showed higher hypermethylation of HIN-1 in both tumor grades II and III which indicates that HIN-1 gene is epigenetically at advanced stage in both TNBC and Non-TNBC and can be used as a good prognostic markers for Saudi’s patients. Other found significant high frequency of HIN-1 gene promoter hypermethylation in tumor at an advanced stage compared to those at early stages (Lee et al., 2010).

PAX5 gene plays an important role in cell differentiation and embryonic development (Palmisano et al., 2003). In the current study, high non-significant frequency of PAX5 hypermethylation was observed in association with tumor grade, size and LN. In breast tumor, PAX5 gene hypermethylation is responsible for gene silencing. Moelans et al. found an association between PAX5 and tumor grade but no association with LN status (Moelans et al., 2011). In addition, PAX5 gene has been implicated in the pathogenesis of small lymphocytic lymphoma cancer and advanced-stage glioblastoma (O’Brien et al., 2011). DNA methylation was linked to the transcriptional silencing of PAX5 genes in murine myeloma cells (Danbara et al., 2002).

TWIST gene belongs to the basic-helix-loop-helix family of an anti-apoptotic and prometastatic transcription factors (Sung et al., 2011). TWIST gene can act as oncogene that inhibits apoptosis in a p53-independent manner and may be important to the biology of tumor distant metastasis (Escobar-Cabrera Je, 2013). It may also alter cellular growth via its effects upon chromatin structure and may be important to the biology of tumor transformation (Sakuma et al., 2007). In the current study, Cyclin D2, a member of D-type cyclins, is implicated in cell cycle regulation, differentiation and malignant transformation (Sakuma et al., 2007). In the current study, Cyclin D2 hypermethylation was higher in both BC groups than in benign breast tissue and it was significantly increased with tumor grade in non-TNBC. Previous findings on invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) showed a trend towards increased Cyclin D2 methylation progressing from low-grade ductal in situ (DCIS) breast cancers grades-I and -II 27% to high-grade DCIS 39% to IDC 52% (Evron et al., 2001; Lehmann et al., 2002).

CDH13 gene can act as a tumor suppressor gene and its expression is decreased in invasive carcinomas resulting in decreasing cell-cell adhesion enhancing tumor progression and invasion (Eillmann et al., 2012). We reported a significant increase in CDH13 gene hypermethylation in TNBC compared to Non-TNBC and was increased in LN positive TNBC cases. This increase is due to the association between this gene with the hormone receptor (Feng et al., 2007). Similarly, more frequently CDH13 hypermethylation was observed in invasive adenoma than in non-invasive adenoma and was associated with high grade (Kornegoor et al., 2012). Also, in breast cancer cell line higher hypermethylation of CDH13 was found and rare in non-malignant and control tissues (Jung et al., 2013). Therefore, the suppression of CDH13 gene by methylation is associated with tumor formation and can be used as a marker for breast cancer development and invasion. RARβ1 is involved in regulation of cellular growth inhibition and apoptosis. Our study established that RARβ1 promoter is frequently hypermethylated in both TNBC and non-TNBC. RARβ1 gene mediates the growth inhibitory effects of retinoic acids in breast cancer cells and also several studies established RARβ1 gene promoter hypermethylation in breast carcinoma (Raffo et al., 2000; Weiwei et al., 2007). Hypermethylation of RARβ was correlated with HER2-positive tumors and with poor prognosis (Mehrotra et al., 2004). RARβ gene can act as a tumor suppressor gene and loss of its expression is found in variety of tumors (Liu et al., 2011). These data provide evidence that hypermethylation is the major mechanism involved in RARβ gene silencing which resulted in impaired RARβ function during BC development. In conclusion, data from this study suggest that the epigenetic event clearly observed in TNBC and Non-TNBC patients might be used as marker for Saudi’s BC. Moreover, this study highlights the promoter methylation of specific genes involved in different molecular pathways.
detoxification, proapoptotic gene that potentially inhibits metastasis, tissue differentiation, regulate expression of tissue-specific genes, tumor suppressor gene and transcription factor. Information from this study may be useful in epigenetic therapy for breast cancer.

Acknowledgements

Authors thank the Deanship of Scientific Research at KSU for funding this work through the research group project no. RGP-VPP-142.

References

Aboserea M, Abdelgawad Mwafik W (2011). Early detection of breast cancer among females at fakous district, sharqia governorate, egypt. Life Science J, 8, 196-203.
AlTamimi DM, Shawarby MA, Ahmed A, et al (2010). Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study. BMC Cancer, 10, 223.
Asemi Z, Jazayeri S, Najafi M, et al (2012). Effect of daily consumption of probiotic yogurt on oxidative stress in pregnant women: a randomized controlled clinical trial. Ann Nutr Metab, 60, 62-8.
Askari M, Sobti RC, Nikbakht M, et al (2013). Promoter hypermethylation of tumour suppressor genes (p14/ARF and p16/INK4a): case-control study in North Indian population. Mol Biol Rep, 40, 4921-8.
Bae YK, Shim YR, Choi JH, et al (2005). Gene promoter hypermethylation in tumors and plasma of breast cancer patients. Cancer Res Treat, 37, 233-40.
Cho NY, Kim JH, Moon KC, et al (2009). Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch, 454, 17-23.
Cho YH, Shen J, Gammon MD, et al (2012). Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res Treat, 131, 197-205.
Dai D, Dong XH, Cheng ST, et al (2014). Aberrant promoter methylation of HIN-1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis. Tumour Biol, 35, 8209-16.
Danbara M, Kameyama K, Higashihara M, et al (2002). DNA methylation dominates transcriptional silencing of Pax5 in terminally differentiated B cell lines. Mol Immunol, 38, 1161-6.
Das PMSingal R (2004). DNA methylation and cancer. J Clin Oncol, 22, 4632-42.
Demokan S, Chuang A, Suoglu Y, et al (2012). Promoter methylation and loss of p16(INK4a) gene expression in head and neck cancer. Head Neck, 34, 1470-5.
Ellmann L, Joshi MB, Resink TJ, et al (2012). BRN2 is a transcriptional repressor of CDH13 (T-cadherin) in melanoma cells. Lab Invest, 92, 1788-800.
Escobar-Cabrera Je BSLaGAG (2013). The role of transcription factor twist in cancer cells. J Genet Syndr Gene Ther, 4, 1-7.
Evron E, Umbricht CB, Korz D, et al (2001). Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res, 61, 2782-7.
Feng W, Orlandi R, Zhao N, et al (2010). Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer, 10, 378.
Feng W, Shen L, Wen S, et al (2007). Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res Treat, 9, 57.
Flamini MI, Gauna GV, Sottile ML, et al (2014). Retinoic acid reduces migration of human breast cancer cells: role of retinoic acid receptor beta. J Cell Mol Med, 18, 1113-3.
Gheibi A, Kazemi M, Baradaran A, et al (2012). Study of promoter methylation pattern of 14-3-3 sigma gene in normal and cancerous tissue of breast: a potential biomarker for detection of breast cancer in patients. Adv Biomed Res, 1, 80.
Gypas F, Bei ES, Zervakis M, et al (2011). A disease annotation study of gene signatures in a breast cancer microarray dataset. Conf Proc IEEE Eng Med Biol Soc, 2011, 5551-4.
Hamamori Y, Sartorelli V, Ogryzko V, et al (1999). Regulation of histone acetyltransferases p300 and PCAF by the SHLH protein twist and adenooviral oncoprotein E1A. Cell, 96, 405-13.
Henrique R, Costa VL, Cerveira N, et al (2006). Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl), 84, 911-8.
Jentzmk F, Krause H, Reichelt U, et al (2012). GSTP1 CpG island hypermethylation for DNA-based detection of occult tumor cells in surgical margins after radical prostatectomy. World J Urol, 30, 541-6.
Jha AK, Nikbakht M, Jain V, et al (2012). p16(INK4a) and p15(INK4b) gene promoter methylation in cervical cancer patients. Oncol Lett, 3, 1331-5.
Jung EJ, Kim IS, Lee EY, et al (2013). Comparison of methylation profiling in cancerous and their corresponding normal tissues from korean patients with breast cancer. Ann Lab Med, 33, 431-40.
Kaczmarczyk G, Lewandowski R, Trautso W, et al (2012). Cytological examination of pleural cavity lavage accompanied by the study of gene promoter hypermethylation of p16 and O6-methylguanine-DNA-methyltransferase genes in diagnostics of non-small cell lung cancer metastatic changes into pleura. Contemp Oncol (Poloz), 16, 322-7.
Khor GH, Froemming GR, Zain RB, et al (2013). DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma. Int J Med Sci, 10, 1727-39.
Kornegoor R, Moelans CB, Verschuuren-Maes AH, et al (2012). Promoter hypermethylation in male breast cancer: analysis by multiple ligation-dependent probe amplification. Breast Cancer Res, 14, 101.
Krop IE, Sgroi D, Porter DA, et al (2001). HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci USA, 98, 9796-801.
Lee JS, Fackler MJ, Lee JH, et al (2010). Basal-like breast cancer displays distinct patterns of promoter methylation. Cancer Biol Ther, 9, 1017-24.
Lehmann U, Celikkaya G, Hasemeier B, et al (2002). Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res, 62, 6634-8.
Liu X, Nugoli M, Laferriere J, et al (2011). Stromal retinoic acid receptor beta promotes mammary gland tumorigenesis. Proc Natl Acad Sci U S A, 108, 774-9.
Mehrotra J, Vali M, McVeigh M, et al (2004). Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res, 10, 3104-9.
Mishra DK, Chen Z, Wu Y, et al (2010). Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther, 9, 33-45.
Moelans CB, Verschuuren-Maes AHvan Diest PJ (2011). Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and
